PET radiopharm proposed reg "unjustifiably" reverses FDA nuclear pharmacy policy -- medical groups.
Executive Summary
PET RADIOPHARM PROPOSED REG "UNJUSTIFIABLY" REVERSES FDA POLICY, ASHP (the American Society of Health-system Pharmacists), the American Pharmaceutical Association and the American College of Nuclear Physicians/Society of Nuclear Medicine maintain in a July 27 joint letter to FDA Commissioner Kessler. The coalition wrote to express its "profound concern regarding the direction the FDA is taking in regulating PET (positron emission tomography) radiopharmaceuticals."